NCT03627182 - Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

April 26, 2018

Primary Completion Date

March 29, 2022

Study Completion Date

February 10, 2023

Conditions

Type2 Diabetes

Interventions

DRUG

CKD-501 0.5mg

CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745

DRUG

Placebo

"Placebo, orally, 1 tablet once a day for 24weeks with D150 and D745.~CKD-501 placebo will be changed to CKD-501 from extension stydy to EOS(end of study)."

Trial Locations (1)

Unknown

RECRUITING

Severance Hospital, Yonsei University Health System, Seoul